The prolyl oligopeptidase inhibitor KYP‑2047 is not readily bioavailable to bloodstream form trypanosomes and human myelocytic leukemia cells. Journal of Pharmaceutical Negative Results, [S. l.], v. 6, n. 1, p. 7–10, 2015. Disponível em: https://mail.pnrjournal.com/index.php/home/article/view/84.. Acesso em: 14 may. 2026.